ZGZaur Gasimov

Zaur Gasimov

*This is an algorithmically generated author record based on publicly available information.

Zaur Gasimov has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Key considerations and recommendations for recruiting older adults in physical activity studies

    by Sunwoo Lee, Magdalena Cyma-Wejchenig, Veysel Alcan, Ana Morais, Antoine Langeard, Elpidio Attoh-Mensah, Eleni Epiphaniou, Melanie Mack, Sebahat Gözüm, Aysegul Ilgaz, et al.

    Despite substantial evidence supporting the benefits of physical activity (PA) for older adults, participation rates remain low due to physical, psychological, social, and institutional barriers. Recruiting older adults for PA studies thus presents significant challenges, particularly for socially vulnerable populations and those facing digital literacy limitations in technology-assisted PA interventions. The present study aimed to articulate and establish a consensus among multidisciplinary and multinational PA experts regarding key considerations and requirements for designing and implementing recruitment of older adults for PA studies. This study employed a mixed-methods consensus approach integrating a structured formal consensus process with a two-round Delphi survey. Through face-to-face and online discussions, an expert panel group formulated 104 initial recommendations regarding the recruitment of older adults for PA studies. In the first Delphi round, 42 external experts assessed the relevance of each recommendation, and recommendations with a ≥ 70% agreement threshold were considered consensual. The second round included 60 refined recommendations that were evaluated by 31 experts. A final consensus was reached through iterative expert panel discussions. Of the 104 initial recommendations, 52 (50%) met the inclusion threshold during the first round. In the second round of Delphi, 36 of the 60 revised recommendations (60%) achieved consensus, with agreement ranging from 71.0 to 96.8%. The final consensus process established 34 key recommendations categorized into four domains: (1) ethical principles (71.7–93.5%), (2) informed consent (71.0–96.8%), (3) stakeholder engagement (61.3–83.9%), and (4) recruitment strategies for technology-assisted PA interventions (74.2–87.1%). However, there remains a lack of consensus on the extent to which sociocultural diversity and differences in sample representation should be addressed. This study provides expert-driven, consensus-based recommendations to improve the recruitment of older adults for PA studies. Adherence to ethical considerations, informed consent procedures, stakeholder collaboration, and tailored strategies for technology-assisted interventions were highlighted. These findings offer practical guidance for researchers and practitioners in planning and obtaining adequate participation in PA studies involving older adults.


  • Open Access

    AHU 377 is commercially hidden molecula?

    by Zaur Gasimov

    ARNI-drug, which consists of two components: the blocker of angiotensin receptors -valsartan and the neprilysin inhibitor-sacubitril. As a rule, the drugs available in cardiological practice, both two-component and fixed 3 or more component, consist of a combination of drugs that are successfully used as monotherapy. Examples include calcium antagonists, β-blockers, hydrochlorothiazide, indapamide, valsartan, perindopril, etc. All these drugs have been used successfully for many years as monotherapy, and nowadays, both as monotherapy and in combinations.But sacubitril is only drug in cardiovascular practice which is not recommended as monotherapy,only as combination – sacubitril/valsartan. LCZ 696 were represented by drug makers as very difficult to create, even at 696 attempt, < monolith molecule>. Cause of ? The reason is not entirely clear and, as I understand it, is explained by the necessity of compulsory fusion into a for the simultaneous release of both components of both valsartan and sacubitrile so that valsartan mitigates the negative effect of sacubitril caused NEP-dependent degradation of angiotensin II.Weak explanation,isn’t it? But No sacubitril monotherapy studies were conducted. However, a sacubitril 200 mg monotherapy arm of 165 patients was included in the HTN study CLCZ696A2201. A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension. In monotherapy arm, participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan.